Kun Tao
Managing Partner
YAFO Capital
Topic
What to expect from out licensing to China transactions and How
Mr. Tao will discuss the following points:
- 1. Type of Chinese pharmaceutical companies and their preference
- 2. How to approach maximum number of companies
- 3. How to evaluate an asset
Free Registration
Please click here
Registration is free but required (max 100 registrants).
Speakers
Mr. Tao is a Managing Partner of Yafo Capital and the Head of U.S. Business. Mr. Tao has more than 15 years’ experience as an analyst and consultant working with public and private companies in North America and China across a variety of technology sectors. He has extensive knowledge on market analysis, business development, due diligence, and operations for U.S. – China cross-border transactions. He previously worked at William O’neil + Co. where he developed its Chinese operations and oversaw Chinese research. Before that, he was Director of Chinese research and senior research analyst at Roth Capital Partners where he supported over $2 billion cross-border equity financings.
Mr. Tao is a CFA Charter holder and has a MBA from University of California, Riverside.
When
Oct 3rd (Sat), 2020
7:00 – 8:30 pm
Where
Zoom
Free Registration
Please click here
Registration is free but required (max 100 registrants).
Questions
Email: Sabpa.ocla@gmail.com
